Migraine prevention
- 1Professor of Neurology, Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
- 2Professor of Neurology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- Professor D W Dodick, Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, Arizona 85259, USA; Dodick.David{at}mayo.edu
Abstract
Preventive medications reduce migraine frequency and severity, and improve migraine-specific quality of life. Recent evidence also suggests that these same medications enhance the patient’s response to acute migraine therapies, and may also reduce the likelihood of developing chronic daily headache. However, many patients who should receive or be offered preventive treatment are not. Most patients can be successfully managed when patient and physician expectations are realistic and aligned, the selection of preventive medications is individualised, and the initiation and titration strategy is appropriate and carefully followed. Rational combinations of preventive medications may also be useful. This review provides an evidence and experience-based approach to the preventive treatment of migraine.
